<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">920</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2020-1-2-3-17-19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Imports of pharmaceutical substances to Russia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nechaeva</surname><given-names>Yuliya</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">DSM Group</aff><pub-date date-type="epub" iso-8601-date="2020-12-01" publication-format="electronic"><day>01</day><month>12</month><year>2020</year></pub-date><issue>1-3</issue><fpage>17</fpage><lpage>19</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2020,</copyright-statement><copyright-year>2020</copyright-year></permissions><abstract>The availability of pharmaceutical substances is key to successful operation of drug manufacturers. Today there are not many companies in the territory of Russia that are intimately involved in the manufacture of pharmaceutical raw materials. And this is one of the major setbacks in the issue of drug safety. That is why special attention was paid to the manufacture of substances in developing the Pharma-2030 strategy for pharmaceutical industry. The main course is set for increase of the domestic production of raw materials to provide domestic industry with sufficient amount of such materials. Moreover, production output should be increased to the volumes that will make it possible to establish active export of substances to the world market.</abstract><kwd-group xml:lang="en"><kwd>import</kwd><kwd>pharmaceutical substances</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>импорт</kwd><kwd>фармацевтические субстанции</kwd></kwd-group></article-meta></front><body></body><back/></article>
